Revance Marks Significant Milestone with One Million Vials of DAXXIFY® Distributed in the U.S.

Revance Marks Major Milestone in Aesthetic Medicine

Revance Therapeutics, a rapidly growing company in the aesthetics and skincare sector, proudly announces the distribution of its one millionth vial of DAXXIFY® in the United States. This significant achievement comes just three years after the FDA granted approval for DAXXIFY® (daxibotulinumtoxinA-lanm), highlighting its status as the fastest-growing neurotoxin in the U.S. market.

DAXXIFY® is pioneering due to its proprietary peptide formulation, setting it apart as the only neurotoxin that is devoid of human or animal components. This innovative frown line treatment represents a considerable leap in neurotoxin technology, marking the first substantial advancement in over two decades. Its unique clinical profile allows for a quick onset of action and the capability to smooth deep lines with enduring results.

Dr. Conor Gallagher, Chief Scientific Officer of Revance, stated, "Reaching the milestone of one million vials is an important moment for both DAXXIFY® and the field of aesthetic medicine. This achievement reflects the strong trust our provider partners have in our peptide formula and underscores the value of innovations that translate to tangible clinical results. We continue to be inspired by the accumulating real-world evidence and are committed to expanding the science and data that support DAXXIFY®.”

The growing demand for quality ingredients among patients is more prominent than ever, with consumers increasingly discerning about the products and treatments they choose. DAXXIFY® has successfully positioned itself as a reliable option for those seeking frown line treatments, making this accomplishment even more noteworthy.

Revance is dedicated to advancing the field of aesthetic medicine, with a robust portfolio that includes DAXXIFY® as well as other innovative products like the Teoxane RHA® Collection and SkinPen®, a leading microneedling device. The company continues to bolster its global presence, operating in over 60 countries while simultaneously exploring opportunities to enter new markets. Revance's steady commitment to innovation ensures they address the evolving needs of patients and consumers alike across various stages of life.

DAXXIFY® is not just about physical appearance; it is an embodiment of scientific advancement and patient-centric solutions in the aesthetic space. As Revance moves forward, the emphasis remains on pushing boundaries, enhancing patient outcomes, and maintaining confidence in the efficacy and safety of their products. For further information, please visit Revance.com and DAXXIFY.com.

In conclusion, Revance's distribution of one million vials of DAXXIFY® signifies a robust foundation for further growth and exploration in the aesthetics market, marking a pivotal moment in both the company’s history and the industry at large.